June, 2023
Equaly is delighted to announce the appointment of a new Chief Executive Officer
Mr. François Boitquin has joined our team as the new Chief Executive Officer (CEO) in June 2023. With his wealth of experience and proven leadership skills, Mr. Boitquin brings a fresh perspective and strategic vision to our company.
Mr. Boitquin visionary mindset and exceptional management skills make him the ideal fit to lead Equaly SA into the future.

March, 2022
Equaly is thrilled to announce the appointment of a Chief Business Officer
Mr. Fabrice du Chastel has joined our company as the Chief Business Officer (CBO) as from March 2022. With his extensive experience and strategic vision, we are confident that Mr. du Chastel will play a crucial role in driving our company’s growth and expanding our business opportunities.

December 02, 2021
Equaly is pleased to announce
that it has been selected by the US-based magazine Pharma Tech Outlook as one of the most innovative biotech companies in the field of Immunotherapy in Europe for the Year 2022.
Equaly: “Unlocking the Potential of Innate Immune System by Jean-Marie Saint-Remy, Founder and CSO”.

The article is accessible by this link.

November 19, 2021
Equaly is proud to announce
the setting up of a new Board of Directors covering expertise in Science, Corporate Finance and Biotech Development Strategy.

August 27, 2021
Equaly announces the completion of a third capital increase
A capital increase of more than 2 M€ has been obtained on August 27, 2021, from a panel of private investors to support Equaly’s projects according to its main technology platforms on replacement and gene therapy, gene editing and novel vaccination approaches for viral diseases and tumors.

September 23, 2020
Equaly announces to be awarded a Walloon Region subsidy for the therapy of orphan diseases

A subsidy of €2.8 million over a period of 3 years will be devoted to the development of novel enzyme replacement therapies for the treatment of both Fabry and Pompe diseases, as well as novel approaches for gene therapy of such diseases.
Fabry and Pompe diseases are two examples of lysosomal storage diseases due to a lack of a functional enzyme essential to glycogen degradation. Such diseases are lethal in their full expression, but are also associated to a number of neurodegenerative syndromes in later life.
The production of non-immunogenic forms of specific enzymes for replacement therapy and of non-immunogenic variants of viral vectors required for gene therapy, according to Equaly’s proprietary technology, should lead to substantial benefit for patients, if not to a cure for such diseases. ”